Spire Wealth Management’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-600
Closed -$35K 2925
2021
Q3
$35K Hold
600
﹤0.01% 1618
2021
Q2
$48K Hold
600
﹤0.01% 1500
2021
Q1
$50K Buy
+600
New +$60.9K ﹤0.01% 1713

Other funds holding AXDX

Spire Wealth Management's AXDX Position: Q4 2021 in Review

Spire Wealth Management sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 600 shares — an estimated $35K sold.

Spire Wealth Management first reported a position in AXDX in Q1 2021 and held it in 3 quarters. The position peaked at $50K in Q1 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

  • Spire Wealth Management reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Spire Wealth Management sold 600 Accelerate Diagnostics shares in Q4 2021, an estimated $35K.
  • Spire Wealth Management first reported a position in Accelerate Diagnostics in Q1 2021 and held it in 3 quarters.
  • Spire Wealth Management's Accelerate Diagnostics position peaked at $50K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on Spire Wealth Management's 13F filing for Q4 2021, filed 14 Jan 2022.